Cyramza (ramucirumab) combined with EGFR inhibitor Tarceva (erlotinib) were approved in June 2020 as the first-line treatment for metastatic NSCLC patients with EGFR exon 19 deletions or exon 21 (L858R) mutation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.